A Single-arm, Open-label, Phase I Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis
Latest Information Update: 20 Feb 2025
At a glance
- Drugs Rovadicitinib (Primary)
- Indications Haemophagocytic lymphohistiocytosis
- Focus Adverse reactions
- Sponsors Chia Tai Tianqing Pharmaceutical Group
Most Recent Events
- 09 Sep 2020 Status changed from not yet recruiting to recruiting.
- 02 Apr 2020 New trial record